These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31494098)

  • 1. Safety of anti-TNF biologics in paediatric inflammatory bowel disease.
    Ruemmele FM
    Lancet Gastroenterol Hepatol; 2019 Nov; 4(11):813-815. PubMed ID: 31494098
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first line therapy in inflammatory bowel disease.
    Pariente B; Blondeaux A
    Aliment Pharmacol Ther; 2018 Sep; 48(6):683-684. PubMed ID: 30132941
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors' reply.
    Lee HH; Bae JM; Lee BI
    Aliment Pharmacol Ther; 2018 Sep; 48(6):684-685. PubMed ID: 30132943
    [No Abstract]   [Full Text] [Related]  

  • 4. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.
    Nyboe Andersen N; Pasternak B; Friis-Møller N; Andersson M; Jess T
    BMJ; 2015 Jun; 350():h2809. PubMed ID: 26048617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications of biologics in inflammatory bowel disease.
    Sousa P; Allez M
    Curr Opin Gastroenterol; 2015 Jul; 31(4):296-302. PubMed ID: 26039721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of infections with biological agents.
    Kopylov U; Afif W
    Gastroenterol Clin North Am; 2014 Sep; 43(3):509-24. PubMed ID: 25110256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists.
    McConachie SM; Wilhelm SM; Bhargava A; Kale-Pradhan PB
    Ann Pharmacother; 2018 Jun; 52(6):571-579. PubMed ID: 29363355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of anti-TNF therapy (biologics) in the treatment of chronic inflammatory bowel disease in children].
    Kolacek S
    Acta Med Croatica; 2013 Apr; 67(2):89-92. PubMed ID: 24471292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
    Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of infections associated with biological treatment in inflammatory bowel disease.
    Andersen NN; Jess T
    World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging biologics in inflammatory bowel disease.
    Chan HC; Ng SC
    J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.
    Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Rasmussen BK; Avlund S; Olesen TB; Hoffmann HJ; Thomsen MK; Thomsen VØ; Frydenberg M; Nexø BA; Sode J; Vogel U; Andersen V
    Pharmacogenomics J; 2014 Dec; 14(6):526-34. PubMed ID: 24776844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic drugs for inflammatory bowel disease.
    Yanai S; Matsumoto T
    Nihon Rinsho; 2017 Mar; 75(3):403-407. PubMed ID: 30566782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stopping Biologics in IBD-What Is the Evidence?
    Louis E
    Inflamm Bowel Dis; 2018 Mar; 24(4):725-731. PubMed ID: 29548010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease.
    Shah SB; Hanauer SB
    Rev Gastroenterol Disord; 2008; 8(3):159-68. PubMed ID: 18957923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate-severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight.
    Kammerlander H; Nielsen J; Knudsen T; Kjeldsen J; Friedman S; Nørgård BM
    Inflamm Bowel Dis; 2017 Nov; 23(11):1916-1923. PubMed ID: 28858070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Letter to the Editor: "Failure Rate of Antitumor Necrosis Factor Alpha Biologics in Very Early Onset Inflammatory Bowel Disease".
    Collen LV; Snapper SB
    Inflamm Bowel Dis; 2024 Mar; 30(3):513-514. PubMed ID: 38206353
    [No Abstract]   [Full Text] [Related]  

  • 20. Birth Outcomes in Children Fathered by Men Treated with Anti-TNF-α Agents Before Conception.
    Larsen MD; Friedman S; Magnussen B; Nørgård BM
    Am J Gastroenterol; 2016 Nov; 111(11):1608-1613. PubMed ID: 27619836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.